| Title: | Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150 |
| Authors: | Sho, Takuya Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Yamamoto, Yoshiya Browse this author |
| Furuya, Ken Browse this author |
| Baba, Masaru Browse this author |
| Ogawa, Koji Browse this author |
| Kubo, Akinori Browse this author |
| Tokuchi, Yoshimasa Browse this author |
| Fu, Qingjie Browse this author |
| Yang, Zijian Browse this author |
| Kimura, Megumi Browse this author |
| Kitagataya, Takashi Browse this author |
| Maehara, Osamu Browse this author |
| Ohnishi, Shunsuke Browse this author |
| Nakamura, Akihisa Browse this author |
| Yamada, Ren Browse this author |
| Ohara, Masatsugu Browse this author |
| Kawagishi, Naoki Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Nakai, Masato Browse this author |
| Suzuki, Kazuharu Browse this author |
| Izumi, Takaaki Browse this author |
| Meguro, Takashi Browse this author |
| Terashita, Katsumi Browse this author |
| Takagi, Tomofumi Browse this author |
| Ito, Jun Browse this author |
| Kobayashi, Tomoe Browse this author |
| Miyagishima, Takuto Browse this author |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Keywords: | atezolizumab |
| bevacizumab |
| eligibility criteria of IMbrave150 |
| hepatocellular carcinoma |
| Issue Date: | 15-Aug-2022 |
| Publisher: | MDPI |
| Journal Title: | Cancers |
| Volume: | 14 |
| Issue: | 16 |
| Start Page: | 3938 |
| Publisher DOI: | 10.3390/cancers14163938 |
| Abstract: | Simple Summary The IMbrave150 trial led to the approval of atezolizumab and bevacizumab for the treatment of unresectable hepatocellular carcinoma (HCC). We performed a retrospective multicenter study including 115 patients with unresectable HCC treated with atezolizumab and bevacizumab, revealing that the combination of atezolizumab and bevacizumab is equally effective for patients meeting the IMbrave150 trial eligibility criteria and for patients not meeting these criteria, generally due to a history of systemic therapy, platelet counts < 75 x 10(9)/L, Child-Pugh B, and 2+ proteinuria. However, liver functional reserve should be carefully monitored in patients not meeting the IMbrave150 trial eligibility criteria. The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 x 10(9)/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 +/- 0.43 vs. -2.18 +/- 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/86979 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
